On December 1, 2022 Alentis Therapeutics, the Claudin-1 company, reported that Alberto Toso, Head of Oncology, will present a poster at the ESMO (Free ESMO Whitepaper) Immuno-Oncology Congress in Geneva, Switzerland (and virtually), from 7-9 December 2022 (Press release, Alentis Therapeutics, DEC 1, 2022, View Source [SID1234624656]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, CLAUDIN-1 Targeting Antibodies in Solid Tumors: from ALE.C04 to CLAUDIN-1 Oncology Platform, presents evidence that non-junctional Claudin-1 is overexpressed in different solid tumors, drives T-cell exclusion and resistance to checkpoint inhibitors (CPI). Importantly, the use of non-junctional Claudin-1-targeting monoclonal antibody ALE.C04 restored T-cell infiltration and CPI efficacy in a pre-clinical mouse tumor model.

ALE.C04, Alentis’ lead oncology asset, is the first potential treatment to target CLDN1 to open up the mechanical barrier that characterizes immune-excluded CLDN1+ tumors, thus making the tumors vulnerable to treatment. Based on Alentis’ pre-clinical data, rationale and safety profile, the company plans a Phase 1b trial with ALE.C04 in combination with CPIs in solid tumors, expected to initiate in the second half of 2023.

In November 2022, Alentis published pre-clinical proof-of-concept data, showing Claudin-1 monoclonal antibodies as potential first in-class compounds for HCC, in The Journal of Hepatology: View Source

Poster presentation details are listed below:

Poster title: CLAUDIN-1 Targeting Antibodies in Solid Tumors: from ALE.C04 to CLAUDIN-1 Oncology Platform (Abstract #193P)

Presenter: Alberto Toso, Head of Oncology, Alentis Therapeutics

Authors: A. Toso 1 , G. Teixeira 1 , T. Zimmermann 1 , D. Schmitter 1 , M. Meyer 1 , M. Muller 2 , L. Mailly 2 , T. Baumert 2 , R. Iacone 1 1 Oncology, Alentis Therapeutics AG, Allschwil, Switzerland, 2 UMR_S1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France

Date: Thursday, 8th December 2022

Time: 12:30-13:15 CET

Location: Foyer ABC

Register to join the ESMO (Free ESMO Whitepaper) Immuno-Oncology Congress’ digital platform, here.